An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

NCT03770299 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Circulating Tumor DNA

Interventions

BIOLOGICAL: Nivolumab
DRUG: Vinorelbine
DRUG: Gemcitabine
DRUG: Docetaxel
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Paclitaxel
OTHER: Observation

Sponsor

Bristol-Myers Squibb